151539-32-1

Basic information

• Product Name: 8-[(E)-2-(3-nitrophenyl)ethenyl]-1,3-dipropyl-3,7-dihydro-1H-purine-2,6-dione
• CAS NO: 151539-32-1
• Molecular Formula: C₁₉H₂₁N₅O₄
• Molecular Weight: 383.4011
• Mol File: 151539-32-1.mol

Chemical Properties

• Boiling Point: 629°C at 760 mmHg
• Flash Point: 334.2°C
• Density: 1.339g/cm³
• Vapor Pressure: 9.8E-16mmHg at 25°C
• Refractive Index: 1.659
• CAS DataBase Reference: 8-[(E)-2-(3-nitrophenyl)ethenyl]-1,3-dipropyl-3,7-dihydro-1H-purine-2,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 8-[(E)-2-(3-nitrophenyl)ethenyl]-1,3-dipropyl-3,7-dihydro-1H-purine-2,6-dione(151539-32-1)
• EPA Substance Registry System: 8-[(E)-2-(3-nitrophenyl)ethenyl]-1,3-dipropyl-3,7-dihydro-1H-purine-2,6-dione(151539-32-1)

Safety Data

• Hazardous Substances Data: 151539-32-1(Hazardous Substances Data)

Upstream product

• 81250-34-2 1,3-dipropyl-5,6-diaminouracil 
• 555-68-0 (E)-3-Nitrocinnamic acid 

Downstream Products

• 147700-41-2 (E)-7-Methyl-8-(3-nitrostyryl)-1,3-dipropylxanthine 

Relevant articles and documents

Antidepressants

The present invention relates to an antidepressant containing as an active ingredient a xanthine derivative or a pharmaceutically acceptable salt thereof, the xanthine derivative being represented by Formula (I) : STR1 in which R1, R2, and R3 represent independently hydrogen, lower alkyl, lower alkenyl; R4 represents cycloalkyl, --(CH2)n --R5 (in which R5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or STR2 (in which Y1 and Y2 represent independently hydrogen, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl, STR3 (in which R6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 3), or a substituted or unsubstituted heterocyclic group); and X1 and X2 represent independently O or S.

Therapeutic agent for Parkinson's disease

Agents for the treatment of Parkinson''s disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: STR1 in which R 1, R 2 are R 3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R 4 represents cycloalkyl, --(CH 2) n --R 5 (in which R 5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or STR2 in which Y 1 and Y 2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, STR3 in which R 6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X 1 and X 2 represent independently O or S.

Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists

A series of substituted 8-styryl derivatives of 1,3,7-alkylxanthines was synthesized as potential A2-selective adenosine receptor antagonists, and the potency at rat brain A1- and A2-receptors was studied in radioligand bi